Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 24. Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating ...
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated price target remains the same with $10.00. Patrick Trucchio ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results